Regular Article
Phase II Study of Vinorelbine in the Treatment of Platinum-Resistant Ovarian Carcinoma

https://doi.org/10.1006/gyno.2000.6089Get rights and content

Abstract

Objective. The purpose of this phase II study was to evaluate on an intent-to-treat basis the activity and toxicity of single-agent vinorelbine (VRL) as second-line chemotherapy of patients with platinum-resistant ovarian cancer. Platinum-resistant disease was defined as disease refractory to or relapsing within 12 months after finishing platinum-containing chemotherapy.

Methods. VRL (30 mg/m2) was administered intravenously as a bolus injection days 1 and 8 every 21 days. Initially, four courses of VRL were given. Patients with responding or stable disease received four more courses of VRL to a maximum of eight courses.

Results. Twenty-eight of 33 eligible patients were considered evaluable for response. The overall response rate was 21% (7/33) (95% CI: 7–35). Median time to progression was 3.1 months and median survival was 10.1 months. Toxicity was generally mild. Leukopenia was the dose-limiting toxicity. CALGB grade III/IV infection was observed in 15/0% of patients. The most important nonhematologic toxicities were nausea and constipation. Grade III/IV nausea was observed in 6/0% and grade III/IV constipation in 3/3% of patients. Peripheral neurotoxicity was only a minor problem with no grade III/IV toxicity. No patients stopped treatment because of toxicity and no toxic death was reported.

Conclusion. VRL was generally well tolerated, but the activity in platinum-resistant ovarian cancer was only modest, although fully comparable to other second-line treatments. Further studies are required to define the role of VRL in combination chemotherapy for ovarian cancer.

References (19)

There are more references available in the full text version of this article.

Cited by (50)

  • Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)-KCSG GY10-10

    2015, Gynecologic Oncology
    Citation Excerpt :

    Vinorelbine is a semisynthetic vinca alkaloid. Its activity as a single agent or in combination with other agents for the treatment of platinum-resistant recurrent ovarian cancer has been demonstrated in several phase II studies (Table 1) [8–13]. Vinorelbine has been shown to exert in vitro synergistic effects in combination with gemcitabine and administration of vinorelbine prior to gemcitabine increases the maximum concentration and total area of under curve of gemcitabine [14].

  • Cancers Arising in the Ovary

    2014, Abeloff's Clinical Oncology: Fifth Edition
  • The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab

    2010, Gynecologic Oncology
    Citation Excerpt :

    Primary or secondary platinum resistance signalizes a situation with a dismal prognosis. Several regimens have been investigated, but the results have so far been disappointing with response rates around 20% and little or no convincing effect on survival [1–3]. Most ovarian cancer patients end up being multiresistant to cytostatic therapy and are left with few treatment options.

  • Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

    2009, Seminars in Oncology
    Citation Excerpt :

    The decision of whether and when to use oral etoposide is influenced by the degree of gastrointestinal complications caused by the patient's cancer as she must be able to tolerate oral therapy in order to have a chance of benefit from this agent. Vinorelbine,60-62 cyclophosphamide, ifosfamide,63,64 and melphalan65 also have been used to treat recurrent disease, with response rates ranging from 10% to 20%, and these drugs may be considered for those patients who have continued relative sensitivity to chemotherapy and have received the more commonly used agents. Hexamethylmelamine (RR, 10%-17%)66-71 is an oral agent that is approved for the treatment of patients with recurrent ovarian carcinoma, although its use is limited by gastrointestinal toxicity.

View all citing articles on Scopus
1

To whom correspondence and reprint requests should be addressed. Fax: +45 65 41 29 57. E-mail: [email protected].

View full text